Literature DB >> 16097442

Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis.

Norio Nakamura1, Ryuichiro Kumasaka, Hiroshi Osawa, Hideaki Yamabe, Ken-Ichi Shirato, Takeshi Fujita, Rei-Ichi Murakami, Michiko Shimada, Masayuki Nakamura, Ken Okumura, Kei Hamazaki, Tomohito Hamazaki.   

Abstract

Eicosapentaenoic acid (EPA) is one of the major components of fish oil, which was reported to have antiatherogenic, anti-inflammatory and immune suppressive effects. In the present study, highly purified EPA was administered to patients with lupus nephritis and the effects of EPA on urinary 8-isoprostane, a reliable marker of oxidative stress, were investigated in these patients. Six outpatients (1 man and 5 women), with lupus nephritis diagnosed by renal biopsy, were entered in the study. We administered 1800 mg EPA ethyl-ester (purity > 95%) daily and examined the urinary 8-isoprostane levels and plasma fatty acid composition before and 3 months after EPA treatment. The urinary 8-isoprostane levels were significantly decreased after the treatment compared with those before the treatment (from 530 +/- 113 pg/mg x Cr to 235 +/- 49 pg/mg x Cr, p = 0.02). The EPA levels in the plasma phospholipid (PL) fraction were significantly increased after the treatment (from 3.30 +/- 0.64 mol% to 8.01 +/- 0.47 mol%, p < 0.001). Arachidonic acid (AA) levels in the plasma PL fraction were significantly decreased after the treatment (from 9.47 +/- 0.28 mol% to 7.33 +/- 0.43 mol%, p < 0.001). The ratios of EPA to AA were significantly increased after the treatment (from 0.35 +/- 0.07 to 1.14 +/- 0.16, p < 0.001). Thus, this preliminary study indicated that EPA might exert beneficial effects on lupus nephritis by decreasing the oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16097442

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  7 in total

1.  The interaction between ApoA2 -265T>C polymorphism and dietary fatty acids intake on oxidative stress in patients with type 2 diabetes mellitus.

Authors:  Elham Zamani; Haleh Sadrzadeh-Yeganeh; Gity Sotoudeh; Laleh Keramat; Mohammadreza Eshraghian; Masoumeh Rafiee; Fariba Koohdani
Journal:  Eur J Nutr       Date:  2016-06-06       Impact factor: 5.614

2.  Concentrated fish oil (Lovaza(R)) extends lifespan and attenuates kidney disease in lupus-prone short-lived (NZBxNZW)F1 mice.

Authors:  Ganesh V Halade; Paul J Williams; Jyothi M Veigas; Jeffrey L Barnes; Gabriel Fernandes
Journal:  Exp Biol Med (Maywood)       Date:  2013-06

3.  Positive association between plasma antioxidant capacity and n-3 PUFA in red blood cells from women.

Authors:  A Y Thorlaksdottir; G V Skuladottir; A L Petursdottir; L Tryggvadottir; H M Ogmundsdottir; J E Eyfjord; J J Jonsson; I Hardardottir
Journal:  Lipids       Date:  2006-02       Impact factor: 1.880

4.  Effect of marine omega 3 fatty acids on methylmercury-induced toxicity in fish and mammalian cells in vitro.

Authors:  O J Nøstbakken; I L Bredal; P A Olsvik; T S Huang; B E Torstensen
Journal:  J Biomed Biotechnol       Date:  2012-05-10

5.  Increased Antioxidant Capacity and Pro-Homeostatic Lipid Mediators in Ocular Hypertension-A Human Experimental Model.

Authors:  Mia Langbøl; Sarkis Saruhanian; Thisayini Baskaran; Daniel Tiedemann; Zaynab A Mouhammad; Anne Katrine Toft-Kehler; Bokkyoo Jun; Rupali Vohra; Nicolas G Bazan; Miriam Kolko
Journal:  J Clin Med       Date:  2020-09-15       Impact factor: 4.241

6.  Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus.

Authors:  Cristina Arriens; Linda S Hynan; Robert H Lerman; David R Karp; Chandra Mohan
Journal:  Nutr J       Date:  2015-08-18       Impact factor: 3.271

7.  Requisite Omega-3 HUFA Biomarker Thresholds for Preventing Murine Lupus Flaring.

Authors:  Kathryn A Wierenga; Rita S Strakovsky; Abby D Benninghoff; Lichchavi D Rajasinghe; Adam L Lock; Jack R Harkema; James J Pestka
Journal:  Front Immunol       Date:  2020-08-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.